Dirozalkib (XZP-3621) vs Lorlatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK / ROS1 · full Non-Small Cell Lung Cancer pipeline
Dirozalkib (XZP-3621)
Marketed by Xuanzhu Biopharmaceutical and partners
NCT05204628 · Phase 3 · status unknown
Patients were randomly assigned to XZP-3621 or crizotinib, but the study is open-label rather than blinded, which is a weaker design even though it measures a hard clinical outcome, progression-free survival, against an active standard-of-care comparator. Results have not been posted yet.
No aligned efficacy figure on record for this race.
Lorlatinib
Marketed by Pfizer
NCT03052608 · Phase 3 · active, not recruiting
People were randomized to lorlatinib or the active comparator crizotinib and progression-free survival was read by blinded independent review, with a clear significant result in 296 people. The trial was open-label, so participants and investigators knew the treatment.
Next expected readout: December 2026 · NCT05059522 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dirozalkib (XZP-3621) | Lorlatinib |
|---|---|---|
| PFS, median | —Not reported | 16.6bNCT0197086511 other results
|
| OS, median | —Not reported | 52.5bNCT019708654 other results
|
| ORR | —Not reported | 75.8% vs 57.8%vs CrizotinibNCT030526084 other results
|
| Duration of response, median | —Not reported | 20.9bNCT043620724 other results
|
PFS, median
- Dirozalkib (XZP-3621)
- —Not reported
- Lorlatinib
- 16.6bNCT01970865
11 other results
- 20.6 NCT01970865
- 6.9 NCT01970865
- 7.3 NCT01970865
- 5.5 NCT01970865
- 9.9 NCT01970865
- 12.2 NCT04362072
- 9.7 NCT04362072
- 26.3 NCT03909971
- 5.6 NCT03909971
- 26.3 NCT03909971
- 6.9 NCT03909971
OS, median
- Dirozalkib (XZP-3621)
- —Not reported
- Lorlatinib
- 52.5bNCT01970865
4 other results
- 18.7 NCT01970865
- 20.4 NCT01970865
- 49.7 NCT01970865
- 21.9 NCT03909971
ORR
- Dirozalkib (XZP-3621)
- —Not reported
- Lorlatinib
- 75.8% vs 57.8%vs CrizotinibNCT03052608
4 other results
- 80.5% vs 61.9% NCT03052608
- 70.1% NCT03909971
- 79.1% NCT03909971
- 47.6% NCT03909971
Duration of response, median
- Dirozalkib (XZP-3621)
- —Not reported
- Lorlatinib
- 20.9bNCT04362072
4 other results
- 31.7 NCT03909971
- 10.4 NCT03909971
- 20.9 NCT03909971
- 20.8 NCT03909971
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Dirozalkib (XZP-3621): no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Dirozalkib (XZP-3621): 0 of 4 rows · Lorlatinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lorlatinib |
|---|---|
| Dropout rate | 82.6%a NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 22 more results82.4%100 mg QD NCT01970865 · Phase 1/2 100%200 mg QD NCT01970865 · Phase 1/2 100%150 mg QD NCT01970865 · Phase 1/2 50%100 mg BID NCT01970865 · Phase 1/2 66.7%75 mg BID NCT01970865 · Phase 1/2 83.3%75 mg QD NCT01970865 · Phase 1/2 100%50 mg QD NCT01970865 · Phase 1/2 100%35 mg BID NCT01970865 · Phase 1/2 100%25 mg QD NCT01970865 · Phase 1/2 100%10 mg QD NCT01970865 · Phase 1/2 40%EXP-1 (Phase 2) NCT01970865 · Phase 1/2 74.1%EXP-2 (Phase 2) NCT01970865 · Phase 1/2 70%EXP-3 (Phase 2) NCT01970865 · Phase 1/2 87.7%EXP-4 (Phase 2) NCT01970865 · Phase 1/2 93.5%EXP-5 (Phase 2) NCT01970865 · Phase 1/2 85.1%EXP-6 (Phase 2) NCT01970865 · Phase 1/2 33.3%Japan Lead-In Cohort (LIC) NCT01970865 · Phase 1/2 —100mg NCT04362072 · Phase 4 · registry result, not featured evidence n/a: no completion milestoneLorlatinib NCT04362072 · Phase 4 · registry result, not featured evidence 45%100 mg QD NCT04541706 · Phase 4 · registry result, not featured evidence n/a: no completion milestoneCohort 1 NCT03909971 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort 2 NCT03909971 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 6.7%a NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 22 more results—100 mg QD NCT01970865 · Phase 1/2 —200 mg QD NCT01970865 · Phase 1/2 —150 mg QD NCT01970865 · Phase 1/2 —100 mg BID NCT01970865 · Phase 1/2 —75 mg BID NCT01970865 · Phase 1/2 —75 mg QD NCT01970865 · Phase 1/2 —50 mg QD NCT01970865 · Phase 1/2 —35 mg BID NCT01970865 · Phase 1/2 —25 mg QD NCT01970865 · Phase 1/2 —10 mg QD NCT01970865 · Phase 1/2 —EXP-1 (Phase 2) NCT01970865 · Phase 1/2 —EXP-2 (Phase 2) NCT01970865 · Phase 1/2 —EXP-3 (Phase 2) NCT01970865 · Phase 1/2 —EXP-4 (Phase 2) NCT01970865 · Phase 1/2 —EXP-5 (Phase 2) NCT01970865 · Phase 1/2 —EXP-6 (Phase 2) NCT01970865 · Phase 1/2 —Japan Lead-In Cohort (LIC) NCT01970865 · Phase 1/2 —100mg NCT04362072 · Phase 4 · registry result, not featured evidence 1.4%Lorlatinib NCT04362072 · Phase 4 · registry result, not featured evidence 1%100 mg QD NCT04541706 · Phase 4 · registry result, not featured evidence 1.5%Cohort 1 NCT03909971 · Phase 2 · registry result, not featured evidence 4.8%Cohort 2 NCT03909971 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 34.2%a NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 22 more results58.8%100 mg QD NCT01970865 · Phase 1/2 66.7%200 mg QD NCT01970865 · Phase 1/2 100%150 mg QD NCT01970865 · Phase 1/2 50%100 mg BID NCT01970865 · Phase 1/2 66.7%75 mg BID NCT01970865 · Phase 1/2 50%75 mg QD NCT01970865 · Phase 1/2 33.3%50 mg QD NCT01970865 · Phase 1/2 66.7%35 mg BID NCT01970865 · Phase 1/2 66.7%25 mg QD NCT01970865 · Phase 1/2 100%10 mg QD NCT01970865 · Phase 1/2 50%EXP-1 (Phase 2) NCT01970865 · Phase 1/2 40.7%EXP-2 (Phase 2) NCT01970865 · Phase 1/2 56.7%EXP-3 (Phase 2) NCT01970865 · Phase 1/2 47.7%EXP-4 (Phase 2) NCT01970865 · Phase 1/2 50%EXP-5 (Phase 2) NCT01970865 · Phase 1/2 44.7%EXP-6 (Phase 2) NCT01970865 · Phase 1/2 33.3%Japan Lead-In Cohort (LIC) NCT01970865 · Phase 1/2 32.4%100mg NCT04362072 · Phase 4 · registry result, not featured evidence —Lorlatinib NCT04362072 · Phase 4 · registry result, not featured evidence 22%100 mg QD NCT04541706 · Phase 4 · registry result, not featured evidence 34.3%Cohort 1 NCT03909971 · Phase 2 · registry result, not featured evidence 38.1%Cohort 2 NCT03909971 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a hypertriglyceridaemia 52.3% oedema peripheral 43.6% blood cholesterol increased 39.6% NCT03052608 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 21 more results200 mg QD hypercholesterolaemia 100% affect lability 66.7% aspartate aminotransferase increased 66.7% NCT01970865 · Phase 1/2 75 mg QD hypercholesterolaemia 58.3% blood cholesterol increased 50% fatigue 41.7% NCT01970865 · Phase 1/2 50 mg QD asthenia 66.7% abdominal pain upper 33.3% aspartate aminotransferase increased 33.3% NCT01970865 · Phase 1/2 hypertriglyceridaemia 76.7% hypercholesterolaemia 53.3% oedema peripheral 43.3% NCT01970865 · Phase 1/2 hypertriglyceridaemia 59.3% oedema peripheral 55.6% hypercholesterolaemia 51.9% NCT01970865 · Phase 1/2 hypertriglyceridaemia 69.2% hypercholesterolaemia 58.5% oedema peripheral 38.5% NCT01970865 · Phase 1/2 hypertriglyceridaemia 69.6% hypercholesterolaemia 58.7% blood cholesterol increased 34.8% NCT01970865 · Phase 1/2 alanine aminotransferase increased 100% hypercholesterolaemia 53.2% hypertriglyceridaemia 53.2% NCT01970865 · Phase 1/2 blood cholesterol increased 100% hypertriglyceridaemia 100% alanine aminotransferase increased 66.7% NCT01970865 · Phase 1/2 100mg hypertriglyceridaemia 38% oedema peripheral 36.6% hypercholesterolaemia 33.8% NCT04362072 · Phase 4 · registry result, not featured evidence 100 mg QD hypertriglyceridaemia 58% hypercholesterolaemia 57% weight increased 39% NCT04541706 · Phase 4 · registry result, not featured evidence hypertriglyceridaemia 89.6% weight increased 73.1% hypercholesterolaemia 61.2% NCT03909971 · Phase 2 · registry result, not featured evidence hypertriglyceridaemia 76.2% hypercholesterolaemia 69% alanine aminotransferase increased 45.2% NCT03909971 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 22 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lorlatinib
show 1 more result
show 1 more result
show 11 more results
show 11 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dirozalkib (XZP-3621)'s landscape · Lorlatinib's landscape